A citation-based method for searching scientific literature

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O'Shaughnessy. N Engl J Med 2022
Times Cited: 124



Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, Jose J Ponce Lorenzo, Otto Metzger Filho, Priya Rastogi, W Fraser Symmans, Xuan Liu, Charles E Geyer. Lancet Oncol 2018
Times Cited: 369




List of shared articles



Times cited

Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
Elshad Hasanov, Isabel Pimentel, Mara Cruellas, Mark A Lewis, Eric Jonasch, Judith Balmaña. Am Soc Clin Oncol Educ Book 2022
1

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
Laura M Spring, Yael Bar, Steven J Isakoff. J Natl Compr Canc Netw 2022
2

Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Praveen Vikas, Larissa A Korde, Mark R Somerfield, Dawn L Hershman. JCO Oncol Pract 2022
0

Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
Federica Giugliano, Carmine Valenza, Paolo Tarantino, Giuseppe Curigliano. Expert Opin Investig Drugs 2022
0

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Diogo Silva, Alexandra Mesquita. Breast Cancer (Auckl) 2022
0

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré,[...]. Clin Cancer Res 2022
1

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
Isaiah MacDonald, Nancy A Nixon, Omar F Khan. Curr Oncol 2022
1

Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer.
Mi Jeong Kwon. Arch Pharm Res 2022
2

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Meenakshi Anurag, Eric J Jaehnig, Karsten Krug, Jonathan T Lei, Erik J Bergstrom, Beom-Jun Kim, Tanmayi D Vashist, Anh Minh Tran Huynh, Yongchao Dou, Xuxu Gou,[...]. Cancer Discov 2022
1

Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer-A Review of Molecular Characterisation, Therapeutic Targets and Future Trends.
Karen Pinilla, Lynsey M Drewett, Rebecca Lucey, Jean E Abraham. Front Oncol 2022
0

Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study.
Maximilien Rogé, Julia Salleron, Youlia Kirova, Marin Guigo, Axel Cailleteau, Christelle Levy, Marianne Leheurteur, Rafik Nebbache, Eleonor Rivin Del Campo, Ioana Lazarescu,[...]. Cancers (Basel) 2022
0

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Karama Asleh, Nazia Riaz, Torsten O Nielsen. J Exp Clin Cancer Res 2022
1

Breast cancer: an up-to-date review and future perspectives.
Ruoxi Hong, Binghe Xu. Cancer Commun (Lond) 2022
3

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
Giovanna Garufi, Luisa Carbognin, Francesco Schettini, Elia Seguí, Alba Di Leone, Antonio Franco, Ida Paris, Giovanni Scambia, Giampaolo Tortora, Alessandra Fabi. Cancers (Basel) 2022
2

Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study.
Chen Chen, Xiaoxi Ma, Yanping Li, Jing Ma, Wentao Yang, Ruohong Shui. Pathol Res Pract 2022
0

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report.
Diego Gomez-Puerto, Alba Llop-Guevara, Mara Cruellas, Sara Torres-Esquius, Javier De La Torre, Vicente Peg, Judith Balmaña, Isabel Pimentel. Front Oncol 2022
0

Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
William Jacot, Amélie Lusque, Cécile Vicier, Audrey Mailliez, Thibault de La Motte Rouge, Luc Cabel, Christelle Levy, Anne Patsouris, Isabelle Desmoulins, Lionel Uwer,[...]. Br J Cancer 2022
0


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy